News for CASI Pharmaceuticals Stock (CASI)

Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion Deal

Seeking Alpha • 11/01/20

BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region

PRNewsWire • 10/27/20

CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual Meeting

PRNewsWire • 10/02/20

CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September Conferences

PRNewsWire • 09/11/20

CASI Pharmaceuticals, Inc. (CASI) CEO Dr.

Seeking Alpha • 08/11/20

CASI Pharmaceuticals: Q2 Earnings Insights

Benzinga • 08/10/20

CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results

PRNewsWire • 08/10/20

CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020

PRNewsWire • 08/03/20

5 Stocks to Buy Because of Heavy Insider Buying in July

InvestorPlace • 07/28/20

CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock

PRNewsWire • 07/22/20

CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program

PRNewsWire • 06/08/20

CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference

PRNewsWire • 06/02/20

CASI Pharmaceuticals: 2-Year Price Lows Make For Intriguing Risk-On Buy

Seeking Alpha • 05/13/20

Casi Pharmaceuticals Inc (CASI) CEO Wei-wu He Bought $64,000 of Shares

GuruFocus • 08/20/19

Casi Pharmaceuticals Inc (CASI) CEO Wei-wu He Bought $507,200 of Shares

GuruFocus • 08/15/19